

## Liste publications 2016

### Eqp (J van Meerwijk) : Tolérance Immunitaire dépendante des lymphocytes T

1-Vuddamalay Y, Attia M, Vicente R, Pomié C, Enault G, Leobon B, Joffre O, Romagnoli P, van Meerwijk JP. *Mouse and human CD8(+) CD28(low) regulatory T lymphocytes differentiate in the thymus* **Immunology**. 2016 Jun;148(2):187-96. doi: 10.1111/imm.12600.

2-Decque A\*, Joffre O\*, Magalhaes JG\*, Cossec JC\*, Blecher-Gonen R, Lapaquette P, Silvain A, Manel N, Joubert PE, Seeler JS, Albert ML, Amit I, Amigorena S, Dejean A. *Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing*. **Nat Immunol**. 2016 Feb;17(2):140-9. doi: 10.1038/ni.3342. (equal contributors).

3-Hamdi Y, Soucy P, Adoue V, Michailidou K, Canisius S, Lemaçon A, Droit A, Andrulis IL, Anton-Culver H, Arndt V, Baynes C, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borresen-Dale AL, Brand JS, Brauch H, Brenner H, Broeks A, Burwinkel B, Chang-Claude J, Collaborators N, Couch FJ, Cox A, Cross SS, Czene K, Darabi H, Dennis J, Devilee P, Dörk T, Dos-Santos-Silva I, Eriksson M, Fasching PA, Figueroa J, Flyger H, García-Closas M, Giles GG, Goldberg MS, González-Neira A, Grenaker-Alnæs G, Guénel P, Haeberle L, Haiman CA, Hamann U, Hallberg E, Hooning MJ, Hopper JL, Jakubowska A, Jones M, Kabisch M, Kataja V, Lambrechts D, Le Marchand L, Lindblom A, Lubinski J, Mannermaa A, Maranian M, Margolin S, Marme F, Milne RL, Neuhausen SL, Nevanlinna H, Neven P, Olszow J, Peto J, Plaseska-Karanfilska D, Pylkäs K, Radice P, Rudolph A, Sawyer EJ, Schmidt MK, Shu XO, Southey MC, Swerdlow A, Tollenaar RA, Tomlinson I, Torres D, Truong T, Vachon C, Van Den Ouweland AM, Wang Q, Winqvist R, kConFab/Aocs Investigators, Zheng W, Benitez J, Chenevix-Trench G, Dunning AM, Pharoah PD, Kristensen V, Hall P, Easton DF, Pastinen T, Nord S, Simard J. *Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21*. **Oncotarget**. 2016 Oct 21. doi: 10.18632/oncotarget.12818. [Epub ahead of print]

### Eqp (S Valitutti) : Dynamique moléculaire des interactions lymphocytaires

1-Gravelle P, Do C, Franchet C, Mueller S, Oberic L, Ysebaert L, Larocca LM, Hohaus S, Calmels MN, Frenois FX, Kridel R, Gascoyne RD, Laurent G, Brousset P, Valitutti S, Laurent C. *Impaired functional responses in follicular lymphoma CD8<sup>+</sup>TIM-3<sup>+</sup> T lymphocytes following TCR engagement*. **Oncoimmunology**. 2016 Aug 24;5(10):e1224044.

2-Joullia R, L'Faqihi FE, Valitutti S, Espinosa E. *IL-33 fine tunes mast cell degranulation and chemokine production at the single-cell level*. **J Allergy Clin Immunol**. 2016 Nov 19. pii: S0091-6749(16)31353-7. doi: 10.1016/j.jaci.2016.09.049. [Epub ahead of print]

3-Gaudenzio N, Sibilano R, Marichal T, Starkl P, Reber LL, Cenac N, McNeil BD, Dong X, Hernandez JD, Sagi-Eisenberg R, Hammel I, Roers A, Valitutti S, Tsai M, Espinosa E, Galli SJ. *Different activation signals induce distinct mast cell degranulation strategies*. **J Clin Invest**. 2016 Oct 3;126(10):3981-3998. doi: 10.1172/JCI85538.

4-Petit AE, Demotte N, Scheid B, Wildmann C, Bigirimana R, Gordon-Alonso M, Carrasco J, Valitutti S, Godelaine D, van der Bruggen P. *A major secretory defect of tumour-infiltrating T lymphocytes due to galectin impairing LFA-1-mediated synapse completion*. **Nat Commun**. 2016 Jul 22;7:12242. doi: 10.1038/ncomms12242.

5-Chiaruttini G, Piperno GM, Jouve M, De Nardi F, Larghi P, Peden AA, Baj G, Müller S, Valitutti S, Galli T, Benvenuti F. *The SNARE VAMP7 Regulates Exocytic Trafficking of Interleukin-12 in Dendritic Cells*. **Cell Rep**. 2016 Mar 22;14(11):2624-36. doi: 10.1016/j.celrep.2016.02.055.

6-Khazen R, Müller S, Gaudenzio N, Espinosa E, Puissegur MP, Valitutti S. *Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse*. **Nat Commun**. 2016 Mar 4;7:10823. doi: 10.1038/ncomms10823.

7-Salzer E, Cagdas D, Hons M, Mace EM, Garncarz W, Petronczki ÖY, Platzner R, Pfajfer L, Bilic I, Ban SA, Willmann KL, Mukherjee M, Supper V, Hsu HT, Banerjee PP, Sinha P, McClanahan F, Zlabinger GJ, Pickl WF, Gribben JG, Stockinger H, Bennett KL, Huppa JB, Dupré L, Sanal Ö, Jäger U, Sixt M, Tezcan I, Orange JS, Boztug K. *RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics*. **Nat Immunol**. 2016 Dec;17(12):1352-1360. doi: 10.1038/ni.3575.

8-Blouin CM, Hamon Y, Gonnord P, Boularan C, Kagan J, Viaris de Lesegno C, Ruez R, Mailfert S, Bertaux N, Loew D, Wunder C, Johannes L, Vogt G, Contreras FX, Marguet D, Casanova JL, Galès C, He HT, Lamaze C. *Glycosylation-Dependent IFN-γR Partitioning in Lipid and Actin Nanodomains Is Critical for JAK Activation*. **Cell**. 2016 Aug 11;166(4):920-34. doi: 10.1016/j.cell.2016.07.003. Epub 2016 Aug 4.

## Eqp (N fazilleau / S Guerder) : Cellules présentatrices de l'Antigène et Réponses T CD4

1-Joncker NT, Bettini S, Boulet D, Guiraud M, Guerder S. *The site of tumor development determines immunogenicity via temporal mobilization of antigen-laden dendritic cells in draining lymph nodes*. **Eur J Immunol**. 2016 Mar;46(3):609-18. doi: 10.1002/eji.201545797.

2-Biajoux V, Natt J, Freitas C, Alouche N, Sacquin A, Hemon P, Gaudin F, Fazilleau N, Espéli M, Balabanian K. *Efficient Plasma Cell Differentiation and Trafficking Require Cxcr4 Desensitization*. **Cell Rep**. 2016 Sep 27;17(1):193-205. doi: 10.1016/j.celrep.2016.08.068.

3-Lucca LE, Axisa PP, Aloulou M, Perals C, Ramadan A, Rufas P, Kyewski B, Derbinski J, Fazilleau N, Mars LT, Liblau RS. *Myelin oligodendrocyte glycoprotein induces incomplete tolerance of CD4(+) T cells specific for both a myelin and a neuronal self-antigen in mice*. **Eur J Immunol**. 2016 Sep;46(9):2247-59. doi: 10.1002/eji.201646416.

4-Aloulou M, Carr EJ, Gador M, Bignon A, Liblau RS, Fazilleau N, Linterman MA. *Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells*. **Nat Commun**. 2016 Jan 28;7:10579. doi: 10.1038/ncomms10579.

## Eqp (R Liblau / A Saoudi) : Maladies inflammatoires du système nerveux : mécanismes et traitements

1-Hartmann FJ, Bernard-Valnet R, Quériault C, Mrdjen D, Weber LM, Galli E, Krieg C, Robinson MD, Nguyen XH, Dauvilliers Y, Liblau RS\*, Becher B\*. *High-dimensional single-cell*

analysis reveals the immune signature of narcolepsy. **J. Exp. Med.** 2016 Nov 14;213(12):2621-2633. \* Shared senior authorship

2-Stienne C, Michieletto MF, Benamar M, Carrié N, Bernard I, Nguyen XH, Lippi Y, Duguet F, Liblau RS, Hedrick SM, Saoudi A, Dejean AS. *Foxo3 Transcription Factor Drives Pathogenic T Helper 1 Differentiation by Inducing the Expression of Eomes*. **Immunity**. 2016 Oct 18;45(4):774-787. doi: 10.1016/j.immuni.2016.09.010.

3-Bernard-Valnet R, Yshii L, Quériault C, Nguyen XH, Arthaud S, Rodrigues M, Canivet A, Morel AL, Matthys A, Bauer J, Pignolet B, Dauvilliers Y, Peyron C, Liblau RS. *CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice*. **Proc Natl Acad Sci U S A**. 2016 Sep 27;113(39):10956-61. doi: 10.1073/pnas.1603325113.

4-Yshii LM, Gebauer CM, Pignolet B, Mauré E, Quériault C, Pierau M, Saito H, Suzuki N, Brunner-Weinzierl M, Bauer J, Liblau R. *CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model*. **Brain**. 2016 139(11): 2923-2934.

5-Kassem S, Gaud G, Bernard I, Benamar M, Dejean AS, Liblau R, Fournié GJ, Colacios C, Malissen B, Saoudi A. *A Natural Variant of the T Cell Receptor-Signaling Molecule Vav1 Reduces Both Effector T Cell Functions and Susceptibility to Neuroinflammation*. **PLoS Genet**. 2016 Jul 20;12(7):e1006185. doi: 10.1371/journal.pgen.1006185.

6-Lucca LE, Axisa PP, Aloulou M, Perals C, Ramadan A, Rufas P, Kyewski B, Derbinski J, Fazilleau N, Mars LT, Liblau RS. *Myelin oligodendrocyte glycoprotein induces incomplete tolerance of CD4(+) T cells specific for both a myelin and a neuronal self-antigen in mice*. **Eur J Immunol**. 2016 Sep;46(9):2247-59. doi: 10.1002/eji.201646416.

7-Kieback E, Hilgenberg E, Stervbo U, Lampropoulou V, Shen P, Bunse M, Jaimes Y, Boudinot P, Radbruch A, Klemm U, Kühl AA, Liblau R, Hoevermeyer N, Anderton SM, Uckert W, Fillatreau S. *Thymus-Derived Regulatory T Cells Are Positively Selected on Natural Self-Antigen through Cognate Interactions of High Functional Avidity*. **Immunity**. 2016 May 17;44(5):1114-26. doi: 10.1016/j.immuni.2016.04.018.

8-Nguyen XH, Saoudi A, Liblau RS. *Vaccine-associated inflammatory diseases of the central nervous system: from signals to causation*. **Curr Opin Neurol**. 2016 Jun;29(3):362-71. doi: 10.1097/WCO.0000000000000318.

9-Ramadan A, Lucca LE, Carrié N, Desbois S, Axisa PP, Hayder M, Bauer J, Liblau RS\*, Mars LT\*. *In situ expansion of T cells that recognize distinct self-antigens sustains autoimmunity in the CNS*. **Brain**. 2016 May;139(Pt 5):1433-46. doi: 10.1093/brain/aww032. \* Shared senior authorship

10-Aloulou M, Carr EJ, Gador M, Bignon A, Liblau RS, Fazilleau N, Linterman MA. *Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells*. **Nat Commun**. 2016 Jan 28;7:10579. doi: 10.1038/ncomms10579.

11-Martin-Blondel G, Brassat D, Bauer J, Lassmann H, Liblau RS. *CCR5 blockade for neuroinflammatory diseases--beyond control of HIV*. **Nat Rev Neurol**. 2016 Feb;12(2):95-105. doi: 10.1038/nrneuro.2015.248. Review.

12-Tafti M, Lammers GJ, Dauvilliers Y, Overeem S, Mayer G, Nowak J, Pfister C, Dubois V, Eliaou JF, Eberhard HP, Liblau R, Wierzbicka A, Geisler P, Bassetti CL, Mathis J, Lecendreux M, Khatami R, Heinzer R, Haba-Rubio J, Feketeova E, Baumann CR, Kutalik Z,

Tiercy JM. *Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity*. **Sleep**. 2016 Mar 1;39(3):581-7. doi: 10.5665/sleep.5532.

13-Pedros C, Duguet F, Saoudi A, Chabod M. Disrupted regulatory T cell homeostasis in inflammatory bowel diseases. **World J Gastroenterol**. 2016 Jan 21;22(3):974-95. doi: 10.3748/wjg.v22.i3.974. Review.

14-Mansuy JM, Suberbielle E, Chapuy-Regaud S, Mengelle C, Bujan L, Marchou B, Delobel P, Gonzalez-Dunia D, Malnou CE, Izopet J, Martin-Blondel G. *Zika virus in semen and spermatozoa*. **Lancet Infect Dis**. 2016 Oct;16(10):1106-7. doi: 10.1016/S1473-3099(16)30336-X. No abstract available.

15-Hurlot Q, Fillaux J, Laurent C, Berry A, Hofman P, Marchou B, Delobel P, Brousset P, Martin-Blondel G. *A case report of isolated lymphadenopathy revealing localized leishmanial lymphadenopathy in an asthenic 25-year-old man*. **Medicine (Baltimore)**. 2016 Jul;95(29):e3932. doi: 10.1097/MD.00000000000003932.

16-Fourcade C, Mansuy JM, Dutertre M, Delpech M, Marchou B, Delobel P, Izopet J, Martin-Blondel G. *Viral load kinetics of Zika virus in plasma, urine and saliva in a couple returning from Martinique, French West Indies*. **J Clin Virol**. 2016 Sep;82:1-4. doi: 10.1016/j.jcv.2016.06.011.

17-Branco B, Metsu D, Dutertre M, Marchou B, Delobel P, Recher C, Martin-Blondel G. *Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib*. **Ann Hematol**. 2016 Jun;95(7):1207-9. doi: 10.1007/s00277-016-2684-0. No abstract available.

18-Mansuy JM, Dutertre M, Mengelle C, Fourcade C, Marchou B, Delobel P, Izopet J, Martin-Blondel G. *Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen?* **Lancet Infect Dis**. 2016 Apr;16(4):405. doi: 10.1016/S1473-3099(16)00138-9. No abstract available.

19-Barigou M, Garnier C, Debard A, Mengelle C, Dumas H, Porte L, Delobel P, Bonneville F, Marchou B, Martin-Blondel G. *Favorable outcome of severe human herpes virus-6 encephalitis in an HIV-infected patient*. **AIDS**. 2016 Jan 28;30(3):532-4. doi: 10.1097/QAD.0000000000000973. No abstract available.

20-Voltzenlogel V, Ernst A, de Sèze J, Brassat D, Manning L, Berna F. *Giving meaning to illness: An investigation of self-defining memories in patients with relapsing-remitting multiple sclerosis patients*. **Conscious Cogn**. 2016 Oct;45:200-209. doi: 10.1016/j.concog.2016.09.010.

21-Biotti D, Toulemonde P, Brassat D, Bonneville F. *Teaching NeuroImages: Painful diplopia and Crohn disease: Think about orbital myositis*. **Neurology**. 2016 Aug 16;87(7):e68-9. doi: 10.1212/WNL.0000000000002987. No abstract available.

22-Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, Göbel K, Brassat D, Wiendl H. *Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values*. **Neurol Neuroimmunol Neuroinflamm**. 2016 Jan 27;3(1):e195. doi: 10.1212/NXI.0000000000000195.

23-Axisa PP, Hafler DA. *Multiple sclerosis: genetics, biomarkers, treatments*. **Curr Opin Neurol**. 2016 Jun;29(3):345-53. doi: 10.1097/WCO.0000000000000319.

24-Berry A, Fillaux J, Martin-Blondel G, Boissier J, Iriart X, Marchou B, Magnaval JF, Delobel P. *Evidence for a permanent presence of schistosomiasis in Corsica, France, 2015*. **Euro Surveill**. 2016;21(1). doi: 10.2807/1560-7917.ES.2016.21.1.30100.

25-Pivot D, Debouverie M, Grzebyk M, Brassat D, Clanet M, Clavelou P, Confavreux C, Edan G, Leray E, Moreau T, Vukusic S, Hédelin G, Guillemin F. *Geographical Heterogeneity of Multiple Sclerosis Prevalence in France*. **PLoS One**. 2016 Dec 9;11(12):e0167556. doi: 10.1371/journal.pone.0167556. PubMed PMID: 27936086;

26-Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP). *Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders*. **Mult Scler**. 2016 Nov 24. pii: 1352458516678474. [Epub ahead of print] PubMed PMID: 27885065.

27-Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hauteceur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT,SFSEP, and BEST-MS networks.. *CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy*. **Neurology**. 2016 Dec 6;87(23):2491-2494. PubMed PMID: 27815407.

28-Castel-Lacanal E, Gamé X, Clanet M, De Boissezon X, Brassat D, Rischmann P, Marque P. *Assessment of a program to encourage the multidisciplinary management of urinary disorders in multiple sclerosis*. **Neurourol Urodyn**. 2016 Mar 29. doi:10.1002/nau.23002. [Epub ahead of print] PubMed PMID: 27028504.

29-Biotti D, Toulemonde P, Brassat D, Bonneville F. *Teaching NeuroImages: Painful diplopia and Crohn disease: Think about orbital myositis*. **Neurology**. 2016 Aug 16;87(7):e68-9. doi: 10.1212/WNL.0000000000002987. PubMed PMID: 27527545.

30-Lebrun C, Cohen M, Pignolet B, Seitz-Polski B, Bucciarelli F, Benzaken S, Kantarci O, Siva A, Okuda D, Pelletier D, Brassat D; on behalf SFSEP, BIONAT Network.; RISC.. *Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders*. **J Neurol Sci**. 2016 Sep 15;368:334-6. doi:10.1016/j.jns.2016.07.052. PubMed PMID: 27538659.

31-Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hauteceur P, Tourbah A, Defer G. *Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study*. **J Neurol Sci**. 2016 Apr 15;363:69-76. doi: 10.1016/j.jns.2016.02.012. PubMed PMID: 27000224.

32-Biotti D, Barbieux M, Brassat D. *Teaching Video NeuroImages: Alternating skew deviation with abducting hypertropia following superior colliculus infarction*. **Neurology**. 2016 Mar 1;86(9):e93-4. doi: 10.1212/WNL.0000000000002425. PubMed PMID: 26928363.

33-Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, Göbel K, Brassat D, Wiendl H. *Therapy with natalizumab is associated with high JCV seroconversion and rising*

JCV index values. **Neurol Neuroimmunol Neuroinflamm.** 2016 Jan 27;3(1):e195. doi: 10.1212/NXI.0000000000000195. PubMed PMID: 26848486; PubMed Central PMCID: PMC4733149.

34-Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertelowski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.. *Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.* **Neurology.** 2016 Feb 23;86(8):771-8. doi:10.1212/WNL.0000000000002395. PubMed PMID: 26826205; PubMed Central PMCID:PMC4763805.

35-Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfar A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H. *PML risk stratification using anti-JCV antibody index and L-selectin.* **Mult Scler.** 2016 Jul;22(8):1048-60. doi: 10.1177/1352458515607651. PubMed PMID: 26432858.

36-Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R; *OFSEP and CFSEP.* *Efficacy of rituximab in refractory neuromyelitis optica.* **Mult Scler.** 2016 Jun;22(7):955-9. doi: 10.1177/1352458515602337. PubMed PMID: 26362900.

37-Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttman M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; *European Long-term Follow-up Study Group in Interferon  $\beta$ -1b in Secondary-progressive Multiple Sclerosis.* *A 10-year follow-up of the European multicenter trial of interferon  $\beta$ -1b in secondary-progressive multiple sclerosis.* **Mult Scler.** 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. PubMed PMID: 26362898.

38-Cobo-Calvo Á, Sepúlveda M, Bernard-Valnet R, Ruiz A, Brassat D, Martínez-Yélamos S, Saiz A, Marignier R. *Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications.* **Mult Scler.** 2016 Mar;22(3):312-9. doi: 10.1177/1352458515591071. PubMed PMID: 26209592.

**Eqp 6 (J Izopet) : Infections virales : persistance, réponse de l'hôte et physiopathologie**

1-Abravanel F, Lhomme S, Fougère M, Saune K, Alvarez M, Péron JM, Delobel P, Izopet J. *HEV infection in French HIV-infected patients.* **J Infect.** 2016 Dec 18 (sous presse)

2-El Costa H, Gouilly J, Mansuy JM, Chen Q, Levy C, Cartron G, Veas F, Al-Daccak R, Izopet J, Jabrane-Ferrat N. *ZIKA virus reveals broad tissue and cell tropism during the first trimester of pregnancy.* **Sci Rep.** 2016 Oct 19 (sous presse).

3-Sauné K, Raymond S, Boineau J, Pasquier C, Izopet J. *Detection and quantification of HIV-1 RNA with a fully automated transcription-mediated-amplification assay.* **J Clin Virol.** 2016;84:70-73.

4-Mansuy JM, Suberbielle E, Chapuy-Regaud S, Mengelle C, Bujan L, Marchou B, Delobel P, Gonzalez-Dunia D, Malnou CE, Izopet J, Martin-Blondel G. *Zika virus in semen and spermatozoa.* **Lancet Infect Dis.** 2016;16(10):1106-7.

5-Sauné K, Abravanel F, Haslé C, Boineau J, Mengelle C, Izopet J. *Analytical performance of the VERIS MDx system HCV assay for detecting and quantifying HCV RNA.* **J Clin Virol.** 2016;84:7-11.

6-Nicot F, Cazabat M, Lhomme S, Marion O, Sauné K, Chiabrando J, Dubois M, Kamar N, Abravanel F, Izopet J. *Quantification of HEV RNA by Droplet Digital PCR.* **Viruses.** 2016 Aug 19 (sous presse).

7-Kamar N, Lhomme S, Abravanel F, Marion O, Peron JM, Alric L, Izopet J. *Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis.* **Viruses.** 2016 Aug 15 (sous presse).

8-Lhomme S, Marion O, Abravanel F, Chapuy-Regaud S, Kamar N, Izopet J. *Hepatitis E Pathogenesis.* **Viruses.** 2016 Aug 5 (sous presse).

9-Abravanel F, Métivier S, Chauveau M, Péron JM, Izopet J. *Transmission of HCV NS5A Inhibitor-Resistant Variants Among HIV-Infected Men Who Have Sex With Men.* **Clin Infect Dis.** 2016;63(9):1271-1272.

10-Mansuy JM, Pasquier C, Daudin M, Chapuy-Regaud S, Moinard N, Chevreau C, Izopet J, Mengelle C, Bujan L. *Zika virus in semen of a patient returning from a non-epidemic area.* **Lancet Infect Dis.** 2016;16(8):894-5.

11-Pradat P, Durant J, Brochier C, Trabaud MA, Cottalorda-Dufayard J, Izopet J, Raffi F, Lucht F, Gagnieu MC, Gatey C, Jacomet C, Vassallo M, Dellamonica P, Cotte L; No Nuc No Boost Study Group. *Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naïve HIV patients.* **J Antimicrob Chemother.** 2016;71(11):3235-3241.

12-Fourcade C, Mansuy JM, Dutertre M, Delpech M, Marchou B, Delobel P, Izopet J, Martin-Blondel G. *Viral load kinetics of Zika virus in plasma, urine and saliva in a couple returning from Martinique, French West Indies.* **J Clin Virol.** 2016;82:1-4.

13-Lebreton M, Esposito L, Mengelle C, Del Bello A, Delarche A, Dörr G, Milongo D, Marion O, Izopet J, Kamar N. *A 3-month course of ciprofloxacin does not prevent BK virus replication in heavily immunosuppressed kidney-transplant patients.* **J Clin Virol.** 2016;79:61-7.

14-Trémeaux P, Lhomme S, Chapuy-Regaud S, Peron JM, Alric L, Kamar N, Izopet J, Abravanel F. *Performance of an antigen assay for diagnosing acute hepatitis E virus genotype 3 infection*. **J Clin Virol**. 2016;79:1-5.

15-Mansuy JM, Gallian P, Dimeglio C, Saune K, Arnaud C, Pelletier B, Morel P, Legrand D, Tiberghien P, Izopet J. *A nationwide survey of hepatitis E viral infection in French blood donors*. **Hepatology**. 2016;63(4):1145-54.

16-Sayed IM, Verhoye L, Cocquerel L, Abravanel F, Foquet L, Montpellier C, Debing Y, Farhoudi A, Wychowski C, Dubuisson J, Leroux-Roels G, Neyts J, Izopet J, Michiels T, Meuleman P. *Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver*. **Gut**. 2016 Mar 22. (sous presse).

17-Kamar N, Marion O, Abravanel F, Izopet J, Dalton HR. *Extrahepatic manifestations of hepatitis E virus*. **Liver Int**. 2016;36(4):467-72.

18-Servant-Delmas A, Abravanel F, Lefrère JJ, Lionnet F, Hamon C, Izopet J, Laperche S. *New insights into the natural history of hepatitis E virus infection through a longitudinal study of multitransfused immunocompetent patients in France*. **J Viral Hepat**. 2016;23(7):569-75.

19-Raymond S, Nicot F, Sauné K, Cazabat M, Pasquier C, Massip P, Marchou B, Delobel P, Izopet J. Brief Report: *HIV-1 Tropism During Primary Infections in France: 1996-2014*. **J Acquir Immune Defic Syndr**. 2016;72(4):376-9.

20-Mansuy JM, Dutertre M, Mengelle C, Fourcade C, Marchou B, Delobel P, Izopet J, Martin-Blondel G. *Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen?* **Lancet Infect Dis**. 2016;16(4):405.

21-Abravanel F, Barragué H, Dörr G, Sauné K, Péron JM, Alric L, Kamar N, Izopet J, Champagne E. *Conventional and innate lymphocytes response at the acute phase of HEV infection in transplanted patients*. **J Infect**. 2016;72(6):723-30.

22-Loiseau C, Requena M, Mavigner M, Cazabat M, Carrere N, Suc B, Barange K, Alric L, Marchou B, Massip P, Izopet J, Delobel P. *CCR6(-) regulatory T cells blunt the restoration of gut Th17 cells along the CCR6-CCL20 axis in treated HIV-1-infected individuals*. **Mucosal Immunol**. 2016;9(5):1137-50.

23-Marion O, Abravanel F, Lhomme S, Izopet J, Kamar N. *Hepatitis E in Transplantation*. **Curr Infect Dis Rep**. 2016;18(3):8.

24-Boudjellil R, Elbaz M, Lairez O, Lhomme S, Izopet J, Kamar N. *No evidence of genotype-3 hepatitis E virus-induced myocarditis*. **J Clin Virol**. 2016;76:44.

25-St John EP, Simen BB, Turenchalk GS, Braverman MS, Abbate I, Aerssens J, Bouchez O, Gabriel C, Izopet J, Meixenberger K, Di Giallonardo F, Schlapbach R, Paredes R, Sakwa J, Schmitz-Agheguian GG, Thielen A, Victor M, Metzner KJ, Däumer MP; 454 HIV-1 Alpha Study Group. *A Follow-Up of the Multicenter Collaborative Study on HIV-1 Drug Resistance*



and Tropism Testing Using 454 Ultra Deep Pyrosequencing. **PLoS One**. 2016;11(1):e0146687

26-Raymond S, Nicot F, Carcenac R, Jeanne N, Cazabat M, Requena M, Cuzin L, Delobel P, Izopet J; ANRS 145 MARIMUNO Study Group. *No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy.* **AIDS**. 2016;30(6):965-8.

27-Smith DB, Simmonds P, Izopet J, Oliveira-Filho EF, Ulrich RG, John R, Koenig M, Jameel S, Harrison TJ, Meng XJ, Okamoto H, Van der Poel WH, Purdy MA. *Proposed reference sequences for hepatitis E virus subtypes.* **J Gen Virol**. 2016;97(3):537-42.

28-Kamar N, Marion O, Izopet J. *When Should Ribavirin Be Started to Treat Hepatitis E Virus Infection in Transplant Patients?* **Am J Transplant**. 2016;16(2):727.

29-Daguzan C, Moulin M, Kulyk-Barbier H, Davrinche C, Peyrottes S, Champagne E. *Aminobisphosphonates Synergize with Human Cytomegalovirus To Activate the Antiviral Activity of Vγ9Vδ2 Cells.* **J Immunol**. 2016;196(5):2219-29.

30-Doumerc N, Roumiguie M, Beauval JB, Soulie M, Rischmann P, Kamar N, Sallusto F. *Robotic Kidney Transplantation for Morbidly Obese Patients Excluded from Traditional Transplantation.* **Obes Surg**. 2016 Dec 9. [Epub ahead of print] No abstract available. **Curr Opin Infect Dis**. 2016;29(6):639-644.

31-Rostaing L, Karam B, Congy-Jolivet N, Hage V, Sallusto F, Esposito L, Doumerc N, Debiol B, Guilbeau-Frugier C, Game X, Allal A, Kamar N. *Successful Transplantation in ABO- and HLA-Incompatible Living Kidney Transplant Patients: A Report on 12 Cases.* **Ther Apher Dial**. 2016;20(5):507-516.

32-Rostaing L, Alric L, Kamar N. *Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.* **Transpl Int**. 2016 ;29(12):1257-1265.

33-Milongo D, Kamar N, Del Bello A, Guilbeau-Frugier C, Sallusto F, Esposito L, Dörr G, Blancher A, Congy-Jolivet N. *Allelic and Epitopic Characterization of Intra-Kidney Allograft Anti-HLA Antibodies at Allograft Nephrectomy.* **Am J Transplant**. 2016 Jul 12. (sous presse).

34-Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Kamar N. *Donor-specific antibodies and liver transplantation.* **Hum Immunol**. 2016;77(11):1063-1070.

35-Pouché L, Koitka M, Stojanova J, Woillard JB, Monchaud C, Villeneuve C, Essig M, Abraham J, Le Meur Y, Rerolle JP, Kamar N, Rostaing L, Merville P, Gandia P, Bouchet S, Petersen BS, Marquet P, Picard N. *A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation.* **Pharmacogenomics**. 2016;17(4):375-91.

- 36-Dalton HR, Kamar N, van Eijk JJ, Mclean BN, Cintas P, Bendall RP, Jacobs BC. *Hepatitis E virus and neurological injury*. **Nat Rev Neurol**. 2016;12(2):77-85.
- 37-Del Bello A, Marion O, Milongo D, Rostaing L, Kamar N. *Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients*. **Expert Rev Clin Pharmacol**. 2016;9(2):215-27.
- 38-Guinault D, Ribes D, Delas A, Milongo D, Abravanel F, Puissant-Lubrano B, Izopet J, Kamar N. *Hepatitis E Virus-Induced Cryoglobulinemic Glomerulonephritis in a Nonimmunocompromised Person*. **Am J Kidney Dis**. 2016;67(4):660-3.
- 39-Zhou X, Xu L, Wang W, Watashi K, Wang Y, Sprengers D, de Ruiter PE, van der Laan LJ, Metselaar HJ, Kamar N, Peppelenbosch MP, Pan Q. *Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection*. **J Viral Hepat**. 2016;23(4):294-304.
- 40-Esposito L, Rostaing L, Kamar N. *Successful pregnancy after ABO-incompatible kidney transplantation*. **Transpl Int**. 2016;29(4):506-7.
- 41-Belliere J, Kamar N, Mengelle C, Allal A, Sallusto F, Doumerc N, Game X, Congy-Jolivet N, Esposito L, Debiol B, Rostaing L. *Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia*. **Transpl Int**. 2016;29(3):315-22.
- 42-Villeneuve C, Laroche ML, Essig M, Merville P, Kamar N, Coubret A, Lacroix I, Bouchet S, Fruit D, Marquet P, Rousseau A; EPIGREN study group. *Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation*. **Transplantation**. 2016;100(3):640-7.
- 43-Petrik J, Lozano M, Seed CR, Faddy HM, Keller AJ, Prado Scuracchio PS, Wendel S, Andonov A, Fearon M, Delage G, Zhang J, Shih JW, Gallian P, Djoudi R, Tiberghien P, Izopet J, Dreier J, Vollmer T, Knabbe C, Aggarwal R, Goel A, Ciccaglione AR, Matsubayashi K, Satake M, Tadokoro K, Jeong SH, Zaaijer HL, Zhiburt E, Chay J, Teo D, Chua SS, Piron M, Sauleda S, Echevarria JM, Dalton H, Stramer SL. *Hepatitis E*. **Vox Sang** 2016;110 :93-103.
- 44-Guillois Y, Abravanel F, Miura T, Pavio N, Vaillant V, Lhomme S, Le Guyader FS, Rose N, Le Saux JC, King L, Izopet J, Couturier E. *High proportion of asymptomatic infections in an outbreak of hepatitis E associated with a spit-roasted piglet, France, 2013*. **Clin Infect Dis** 2016;62:351-357.
- 45-JPéron JM, Abravanel F, Guillaume M, Gérolami R, Nana J, Anty R, Pariente A, Renou C, Bureau C, Robic MA, Alric L, Vinel JP, Izopet J, Kamar N. *Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study*. **Liver Int** 2016;36:328-333.
- 46-Gagneux-Brunon A, Nasri D, Terrasse R, Sauné K, Gagnieu MC, Frésard A, Delezay O, Izopet J, Pozzetto B, Lucht F, Bourlet T. *Persistent but not replicating HIV-1 cell-associated*

DNA in semen of long-term ART experienced men. **Curr HIV Res** 2016;14:316-323.

47-Blasco-Perrin H, Abravanel E, Blasco-Baque V, Péron JM. *Hepatitis E, the neglected one.* **Liver Int** 2016;36 Suppl1:130-134.

48-Bujan L, Pasquier C. *People living with HIV and procreation: 30 years of progress from prohibition to freedom?* **Hum Reprod** 2016;31:918-925.

49-Camus C, Matusali G, Bourry O, Mahe D, Aubry F, Bujan L, Pasquier C, Massip P, Ravel C, Zirafi O, Munch J, Roan NR, Pineau C, Dejucq-Rainsford N. *Comparison of the effect of semen from HIV-infected and uninfected men on CD4+ T-cell infection.* **AIDS** 2016;30:1197-1208.

50-Miura T, Lhomme S, Le Saux JC, Le Mehaute P, Guillois Y, Couturier E, Izopet J, Abravanel A, Le Guyader FS. *Detection of hepatitis E virus in sewage after an outbreak on a french Island.* **Food Environ Virol** 2016 ;8 :194-199.

51-Planès R, Ben Hajj N, Leghmari K, Serrero M, BenMohamed L, Bahraoui E. *HIV-1 Tat Protein Activates both the MyD88 and TRIF Pathways To Induce Tumor Necrosis Factor Alpha and Interleukin-10 in Human Monocytes.* **J Virol** 2016;90:5886-98.

52-Metsu D, Seraissol P, Delobel P, Cinq-Frais C, Cuzin L, Izopet J, Chatelut E, Gandia P. *Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?* **Fundam Clin Pharmacol**. Sep 24. 2016 (sous presse).

53-de Boissieu P, Dramé M, Raffi F, Cabie A, Poizot-Martin I, Cotte L, Garraffo R, Delobel P, Huleux T, Rey D, Bani-Sadr F; Dat'AIDS Study Group. *Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.* **Medicine** 2016;95:e4890

54-Hurlot Q, Fillaux J, Laurent C, Berry A, Hofman P, Marchou B, Delobel P, Brousset P, Martin-Blondel G. *A case report of isolated lymphadenopathy revealing localized leishmanial lymphadenopathy in an asthenic 25-year-old man.* **Medicine** 2016;95:e3932.

55-Branco B, Metsu D, Dutertre M, Marchou B, Delobel P, Recher C, Martin-Blondel G. *Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib.* **Ann Hematol**. 2016;95:1207-9.

56-Berry A, Fillaux J, Martin-Blondel G, Boissier J, Iriart X, Marchou B, Magnaval JF, Delobel P. *Evidence for a permanent presence of schistosomiasis in Corsica, France, 2015.* **Euro Surveillance** 2016;21(1).

57-Barigou M, Garnier C, Debard A, Mengelle C, Dumas H, Porte L, Delobel P, Bonneville F, Marchou B, Martin-Blondel G. *Favorable outcome of severe human herpes virus-6 encephalitis in an HIV-infected patient.* **AIDS**. 2016;30:532-4.

58-Allavena C, Katlama C, Cotte L, Roger PM, Delobel P, Cheret A, Duvivier C, Poizot-Martin I, Hoen B, Cabie A, Cheret A, Lahoulou R, Raffi F, Pugliese P; Dat'AIDS Study group. *Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.* **Infect Dis** 2016;48:392-8.

- 59-Garnier C, Martin-Blondel G, Debuissou C, Dubois D, Debard A, Cuzin L, Massip P, Delobel P, Marchou B. *Intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease's lymphadenitis*. **Infection**. 2016;44:23-7.
- 60-Grinyó JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N. *Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial*. **Am J Kidney Dis** 2016 Nov 23 (sous presse).
- 61-Dumortier J, Bailly F, Pageaux GP, Vallet-Pichard A, Radenne S, Habersetzer F, Gagnieu MC, Grangé JD, Minello A, Guillaud O, Kamar N, Alric L, Leroy V. *Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure*. **Nephrol Dial Transplant**. 2016 Oct 19 (sous presse).
- 62-Brown A, Halliday JS, Swadling L, Madden RG, Bendall R, Hunter JG, Maggs J, Simmonds P, Smith DB, Vine L, McLaughlin C, Collier J, Bonsall D, Jeffery K, Dunachie S, Klenerman P, Izopet J, Kamar N, Dalton HR, Barnes E. Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus. **Hepatology**. 2016;64:1934-1950.
- 63-Dalton HR, Kamar N. *Treatment of hepatitis E virus*. **Curr Opin Infect Dis**. 2016;29:639-644.
- 64-Garrouste C, Anglicheau D, Kamar N, Bachelier C, Rivalan J, Pereira B, Caillard S, Aniort J, Gatault P, Soubrier M, Sayegh J, Colosio C, Buisson A, Thervet E, Bouvier N, Heng AE. *Anti-TNF $\alpha$  therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomes*. **Medicine** 2016;95:e5108.
- 65-Del Bello A, Danjoux M, Congy-Jolivet N, Lavayssière L, Esposito L, Muscari F, Kamar N. *Histological long-term outcomes from acute antibody-mediated rejection following ABO-compatible liver transplantation*. **J Gastroenterol Hepatol** 2016 Oct 14 (sous presse)
- 66-Lanfranco L, Olle Delahaye P, Dorr G, Del Bello A, Kamar N. *Late isolated ocular toxoplasmosis in a belatacept-treated kidney transplant patient*. **Transpl Int**. 2016;29:1352-1353.
- 67-Rostaing L, Allal A, Del Bello A, Sallusto F, Esposito L, Doumerc N, Debiol B, Delas A, Game X, Kamar N. *Treatment of large plasma volumes using specific immunoabsorption to desensitize ABO-incompatible kidney-transplant candidates*. **J Nephrol**. 2016;5:90-7.
- 68-Billat PA, Ossman T, Saint-Marcoux F, Essig M, Rerolle JP, Kamar N, Rostaing L, Kaminski H, Fabre G, Otyepka M, Woillard JB, Marquet P, Trouillas P, Picard N, *Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients*. **Pharmacol Res**. 2016;111:501-8.
- 69-Dumortier J, Leroy V, Duvoux C, de Ledinghen V, Francoz C, Houssel-Debry P, Radenne S, d'Alteroche L, Fougereux-Leurent C, Canva V, di Martino V, Conti F, Kamar N, Moreno C, Lebray P, Tran A, Besch C, Diallo A, Rohel A, Rossignol E, Abergel A, Botta-Fridlund D, Coilly A, Samuel D, Duclos-Vallée JC, Pageaux GP. *Sofosbuvir-based treatment of hepatitis*

*C with severe fibrosis (METAVIR F3/F4) after liver transplantation.* **Liver Transpl.** 2016;22(10):1367-78.

70-Huart A, Josse AG, Chauveau D, Korach JM, Heshmati F, Bauvin E, Cointault O, Kamar N, Ribes D, Pourrat J, Faguer S; French Society of Hemapheresis..*Outcomes of patients with Goodpasture syndrome: A nationwide cohort-based study from the French Society of Hemapheresis.* **J Autoimmun.** 2016;73:24-9

71-Coilly A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry P, Duvoux C, Di Martino V, Radenne S, Kamar N, D'Alteroche L, Leroy V, Canva V, Lebray P, Moreno C, Dumortier J, Silvain C, Besch C, Perre P, Botta-Fridlund D, Anty R, Francoz C, Abergel A, Debette-Gratien M, Conti F, Habersetzer F, Rohel A, Rossignol E, Danjou H, Roque-Afonso AM, Samuel D, Duclos-Vallée JC, Pageaux GP; ANRS C023 CUPILT study group..*Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.* **J Hepatol.** 2016;65(4):711-8.

72-Courbebaisse M, Gaillard F, Tissier AM, Fournier C, Le Nestour A, Corr as JM, Slimani-Thevenet H, Martinez F, L on C, Eladari D, Timsit MO, Otal P, Hignette C, Friedlander G, M jean A, Houillier P, Kamar N, Legendre C. *Association of mGFR of the Remaining Kidney Divided by Its Volume before Donation with Functional Gain in mGFR among Living Kidney Donors.* **Clin J Am Soc Nephrol.** 2016;11(8):1369-76.

73-Lorent M, Giral M, Pascual M, Koller MT, Steiger J, Tr berner-Launay K, Legendre C, Kreis H, Mourad G, Garrigue V, Rostaing L, Kamar N, Kessler M, Ladri re M, Morelon E, Buron F, Golshayan D, Foucher Y. *Mortality Prediction after the First Year of Kidney Transplantation: An Observational Study on Two European Cohorts.* **PLoS One.** 2016;11(5):e0155278.

74-Albano L, Buchler M, Cantarovich D, Cassuto E, Cointault O, Mazouz H, Vetromile F, Lecuyer A, Tindel M, Kamar N. *Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation.* **Ann Transplant.** 2016;21:250-61.

75-Naciri Bennani H, Abdulrahman Z, Allal A, Sallusto F, Delarche A, Game X, Esposito L, Doumerc N, Debiol B, Kamar N, Rostaing L. *Early post-transplant complications following ABO-incompatible kidney transplantation.* **J Nephrothol.** 2016;5(1):19-27.

76-Faguer S, Esposito L, Casemayou A, Pirson Y, Decramer S, Cartery C, Hazzan M, Garrigue V, Roussey G, Cointault O, Ho T, Merville P, Devuyst O, Gourdy P, Chassaing N, Bascands JL, Kamar N, Schanstra JP, Rostaing L, Chauveau D.*Calcineurin Inhibitors Downregulate HNF-1  and May Affect the Outcome of HNF1B Patients After Renal Transplantation.* **Transplantation** 2016;100(9):1970-8.

77-Bachelet T, Martinez C, Del Bello A, Couzi L, Keiji S, Guidicelli G, Lepreux S, Visentin J, Congy-Jolivet N, Rostaing L, Taupin JL, Kamar N, Merville P.*Deleterious Impact of Donor-Specific Anti-HLA Antibodies Toward HLA-Cw and HLA-DP in Kidney Transplantation.* **Transplantation** 2016;100(1):159-66.

79-Gasser R, Hamoudi M, Pellicciotta M, Zhou Z, Visdeloup C, Colin P, Braibant M, Lagane B, Negroni M. *Buffering deleterious polymorphisms in highly constrained parts of HIV-1 envelope by flexible regions.* **Retrovirology.** 2016;13(1):50.

80-Benureau Y, Colin P, Staropoli I, Gonzalez N, Garcia-Perez J, Alcamí J, Arenzana-Seisdedos F, Lagane B. *Guidelines for cloning, expression, purification and functional characterization of primary HIV-1 envelope glycoproteins.* **J Virol Methods.** 2016;236:184-95.

81-Quillay H, El Costa H, Duriez M, Marlin R, Cannou C, Madec Y, de Truchis C, Rahmati M, Barré-Sinoussi F, Nugeyre MT, Menu E. *NK cells control HIV-1 infection of macrophages through soluble factors and cellular contacts in the human decidua.* **Retrovirology.** 2016;13(1):39.

82-El Costa H, Quillay H, Marlin R, Cannou C, Duriez M, Benjelloun F, de Truchis C, Rahmati M, Ighil J, Barré-Sinoussi F, Nugeyre MT, Menu E. *The local environment orchestrates mucosal decidual macrophage differentiation and substantially inhibits HIV-1 replication.* **Mucosal Immunol.** 2016;9(3):634-46.

## **Eqp (D Dunia / C Casper) : Pathogénèse des infections virales du système nerveux central adulte et en développement**

1-Charlier CM, Debaisieux S, Foret C, Thouard A, Schiavo G, Gonzalez-Dunia D, Malnou CE. *Neuronal retrograde transport of Borna disease virus occurs in signalling endosomes.* **J Gen Virol.** 2016 Dec;97(12):3215-3224. doi: 10.1099/jgv.0.000652.

2-Mansuy JM, Suberbielle E, Chapuy-Regaud S, Mengelle C, Bujan L, Marchou B, Delobel P, Gonzalez-Dunia D, Malnou CE, Izopet J, Martin-Blondel G. *Zika virus in semen and spermatozoa.* **Lancet Infect Dis.** 2016 Oct;16(10):1106-7. doi: 10.1016/S1473-3099(16)30336-X. No abstract available.

3-Rolland M, Li X, Sellier Y, Martin H, Perez-Berezo T, Rauwel B, Benchoua A, Bessières B, Aziza J, Cenac N, Luo M, Casper C, Peschanski M, Gonzalez-Dunia D, Leruez-Ville M, Davrinche C, Chavanas S. *PPAR $\gamma$  Is Activated during Congenital Cytomegalovirus Infection and Inhibits Neuronogenesis from Human Neural Stem Cells.* **PLoS Pathog.** 2016 Apr 14;12(4):e1005547. doi: 10.1371/journal.ppat.1005547.

4-Ferré CA, Davezac N, Thouard A, Peyrin JM, Belenguer P, Miquel MC, Gonzalez-Dunia D, Szelechowski M. *Manipulation of the N-terminal sequence of the Borna disease virus X protein improves its mitochondrial targeting and neuroprotective potential.* **FASEB J.** 2016 Apr;30(4):1523-33. doi: 10.1096/fj.15-279620.

5-Chavanas S. *Peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) activation: A key determinant of neuropathogeny during congenital infection by cytomegalovirus.* **Neurogenesis** (Austin). 2016 Sep 22;3(1):e1231654.

6-Bonnaud EM, Suberbielle E, Malnou CE. *Histone acetylation in neuronal (dys)function.* **Biomol Concepts.** 2016 May 1;7(2):103-16. doi: 10.1515/bmc-2016-0002.

## Eqp (N Blanchard) : Parasites eucaryotes intracellulaires : immunité et chimiorésistance

1-Cebrian I, Croce C, Guerrero NA, Blanchard N\*, Mayorga LS\*. *Rab22a controls MHC-I intracellular trafficking and antigen cross-presentation by dendritic cells*. **EMBO Rep**. 2016 Dec;17(12):1753-1765. (\* = co-senior)

2-Latour C, Wlodarczyk MF, Jung G, Gineste A, Blanchard N, Ganz T, Roth MP, Coppin H, Kautz L. *Erythroferrone contributes to hepcidin repression in a mouse model of malarial anemia*. **Haematologica**. 2017 Jan;102(1):60-68. doi: 10.3324/haematol.2016.150227.

3-Chu HH, Chan SW, Gosling JP, Blanchard N, Tsitsiklis A, Lythe G, Shastri N, Molina-París C, Robey EA. *Continuous Effector CD8(+) T Cell Production in a Controlled Persistent Infection Is Sustained by a Proliferative Intermediate Population*. **Immunity**. 2016 Jul 19;45(1):159-71. doi: 10.1016/j.immuni.2016.06.013.

4-Sanecka A, Yoshida N, Dougan SK, Jackson J, Shastri N, Ploegh H, Blanchard N, Frickel EM. *Transnuclear CD8 T cells specific for the immunodominant epitope Gra6 lower acute-phase Toxoplasma gondii burden*. **Immunology**. 2016 Nov;149(3):270-279. doi: 10.1111/imm.12643.

5-Menard S, Tchoufack JN, Maffo CN, Nsango SE, Iriart X, Abate L, Tsapi MT, Awono-Ambéné PH, Abega Mekongo FA, Morlais I, Berry A. *Insight into k13-propeller gene polymorphism and ex vivo DHA-response profiles from Cameroonian isolates*. **Malar J**. 2016 Nov 26;15(1):572.

6-Hurlot Q, Fillaux J, Laurent C, Berry A, Hofman P, Marchou B, Delobel P, Brousset P, Martin-Blondel G. *A case report of isolated lymphadenopathy revealing localized leishmanial lymphadenopathy in an asthenic 25-year-old man*. **Medicine (Baltimore)**. 2016 Jul;95(29):e3932. doi: 10.1097/MD.0000000000003932.

7-Boissier J, Grech-Angelini S, Webster BL, Allienne JF, Huyse T, Mas-Coma S, Toulza E, Barré-Cardi H, Rollinson D, Kincaid-Smith J, Oleaga A, Galinier R, Foata J, Rognon A, Berry A, Mouahid G, Henneron R, Moné H, Noel H, Mitta G. *Outbreak of urogenital schistosomiasis in Corsica (France): an epidemiological case study*. **Lancet Infect Dis**. 2016 Aug;16(8):971-9. doi: 10.1016/S1473-3099(16)00175-4.

8-Ménard D, Khim N, Beghain J, Adegnika AA, Shafiu-Alam M, Amodu O, Rahim-Awab G, Barnadas C, Berry A, Boum Y, Bustos MD, Cao J, Chen JH, Collet L, Cui L, Thakur GD, Dieye A, Djallé D, Dorkenoo MA, Eboumbou-Moukoko CE, Espino FE, Fandeur T, Ferreirada-Cruz MF, Fola AA, Fuehrer HP, Hassan AM, Herrera S, Hongvanthong B, Houzé S, Ibrahim ML, Jahirul-Karim M, Jiang L, Kano S, Ali-Khan W, Khanthavong M, Kremsner PG, Lacerda M, Leang R, Leelawong M, Li M, Lin K, Mazarati JB, Ménard S, Morlais I, Muhindo-Mavoko H, Musset L, Na-Bangchang K, Nambozi M, Niaré K, Noedl H, Ouédraogo JB, Pillai DR, Pradines B, Quang-Phuc B, Ramharter M, Randrianarivelojosia M, Sattabongkot J, Sheikh-Omar A, Silué KD, Sirima SB, Sutherland C, Syafruddin D, Tahar R, Tang LH, Touré OA, Tshibangu-wa-Tshibangu P, Vigan-Womas I, Warsame M, Wini L, Zakeri S, Kim S, Eam R, Berne L, Khean C, Chy S, Ken M, Loch K, Canier L, Duru V, Legrand E, Barale JC, Stokes B, Straimer J, Witkowski B, Fidock DA, Rogier C, Ringwald P, Ariey F, Mercereau-Puijalon O; KARMA Consortium. *A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms*. **N Engl J Med**. 2016 Jun 23;374(25):2453-64. doi: 10.1056/NEJMoa1513137.

9-Niaré K, Dara A, Sagara I, Sissoko MS, Guindo CO, Cissé NH, Coulibaly CO, Ringwald P, Benoit-Vical F, Berry A, Djimé AA, Doumbo OK. *In Vivo Efficacy and Parasite Clearance of Artesunate + Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine in Mali*. **Am J Trop Med Hyg**. 2016 Mar;94(3):634-9. doi: 10.4269/ajtmh.15-0503. Epub 2016 Jan 25.

10-Armengol C, Cassaing S, Roques-Malecaze C, Chauvin P, Iriart X, Berry A, Fillaux J. *Time before anti-Toxoplasma IgG seroconversion detection by 7 commercial assays in French pregnant women*. **Diagn Microbiol Infect Dis**. 2016 Oct 22. pii: S0732-8893(16)30349-2. doi: 10.1016/j.diagmicrobio.2016.10.020.

11-Tchioffo MT, Abate L, Boissière A, Nsango SE, Gimonneau G, Berry A, Oswald E, Dubois D, Morlais I. *An epidemiologically successful Escherichia coli sequence type modulates Plasmodium falciparum infection in the mosquito midgut*. **Infect Genet Evol**. 2016 Sep;43:22-30. doi: 10.1016/j.meegid.2016.05.002. Epub 2016 May 3.

## Ep 9 (JP Salles) : Mécanismes moléculaires de la croissance, de l'ostéogenèse et de l'ostéolyse ; biothérapies

1-Boyer JF, Baron M, Constantin A, Degboé Y, Cantagrel A, Davignon JL. *Anti-TNF certolizumab pegol induces antioxidant response in human monocytes via reverse signaling*. **Arthritis Res Ther**. 2016 Mar 1;18:56. doi: 10.1186/s13075-016-0955-8.

2-Burnett LC, LeDuc CA, Sulsona CR, Paull D, Eddiry S, Levy B, Salles JP, Tauber M, Driscoll DJ, Egli D, Leibel RL. *Induced pluripotent stem cells (iPSC) created from skin fibroblasts of patients with Prader-Willi syndrome (PWS) retain the molecular signature of PWS*. **Stem Cell Res**. 2016 Aug 16;17(3):526-530. doi: 10.1016/j.scr.2016.08.008. [Epub ahead of print]

3-Salles JP. *Bone metabolism during pregnancy*. **Ann Endocrinol (Paris)**. 2016 Jun;77(2):163-8. doi: 10.1016/j.ando.2016.04.004.

4-Cessans C, Ehlinger V, Arnaud C, Yart A, Capri Y, Barat P, Cammas B, Lacombe D, Coutant R, David A, Baron S, Weill J, Leheup B, Nicolino M, Salles JP, Verloes A, Tauber M, Cavé H, Edouard T. *Growth patterns of patients with Noonan syndrome: correlation with age and genotype*. **Eur J Endocrinol**. 2016 May;174(5):641-50. doi: 10.1530/EJE-15-0922.

5-Breckpot J, Vercruyssen M, Weyts E, Vandevort S, D'Haenens G, Van Buggenhout G, Leempoels L, Brischoux-Boucher E, Van Maldergem L, Renieri A, Mencarelli MA, D'Angelo C, Méricq V, Hoffer MJ, Tauber M, Molinas C, Castiglioni C, Brison N, Vermeesch JR, Danckaerts M, Sienaert P, Devriendt K, Vogels A. *Copy number variation analysis in adults with catatonia confirms haploinsufficiency of SHANK3 as a predisposing factor*. **Eur J Med Genet**. 2016 Sep;59(9):436-43. doi: 10.1016/j.ejmg.2016.08.003.

6-Salles J, Strelnikov K, Carine M, Denise T, Laurier V, Molinas C, Tauber M, Barone P. *Deficits in voice and multisensory processing in patients with Prader-Willi syndrome*. **Neuropsychologia**. 2016 May;85:137-47. doi: 10.1016/j.neuropsychologia.2016.03.015.

7-Ruyssen-Witrand A, Degboé Y, Cantagrel A, Nigon D, Lukas C, Scaramuzzino S, Allanore Y, Vittecoq O, Schaeffer T, Morel J, Sibilia J, Cambon-Thomsen A, Dieudé P. *Association between RANK, RANKL and OPG polymorphisms with ACPA and erosions in rheumatoid arthritis: results from a meta-analysis involving three French cohorts*. **RMD Open**. 2016 Sep 8;2(2):e000226. doi: 10.1136/rmdopen-2015-000226.



8-Fautrel B, Morel J, Berthelot JM, Constantin A, De Bandt M, Gaudin P, Maillefert JF, Meyer O, Pham T, Saraux A, Solau-Gervais E, Vittecoq O, Wendling D, Erpelding ML, Guillemin F; STPR group of the French Society of Rheumatology. *Validation of flare-ra, a self-administered tool to detect recent or current rheumatoid arthritis flare*. **Arthritis Rheumatol**. 2016 Sep 16. doi: 10.1002/art.39850. [Epub ahead of print]

9-Degboé Y, Constantin A, Nigon D, Tobon G, Cornillet M, Schaefferbeke T, Chiochia G, Nicaise-Roland P, Nogueira L, Serre G, Cantagrel A, Ruysse-Witrand A. *Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort*. **RMD Open**. 2015 Nov 26;1(1):e000180. doi: 10.1136/rmdopen-2015-000180.

10-Chap H. *Forty five years with membrane phospholipids, phospholipases and lipid mediators: A historical perspective*. **Biochimie**. 2016 Jun;125:234-49. doi: 10.1016/j.biochi.2016.04.002. Review.

## **Eqp 10 (R Lesourne) : Bases moléculaires et déterminismes physiologiques de la signalisation dans les lymphocytes T**

1-Cheng D, Deobagkar-Lele M, Zvezdova E, Choi S, Uehara S, Baup D, Bennett SC, Bull KR, Crockford TL, Ferry H, Warzecha C, Marcellin M, de Peredo AG, Lesourne R, Anzilotti C, Love PE, Cornall RJ. *Themis2 lowers the threshold for B cell activation during positive selection*. **Nat Immunol**. 2016 Dec 19. doi: 10.1038/ni.3642. [Epub ahead of print]

2-Zvezdova E, Mikolajczak J, Garreau A, Marcellin M, Rigal L, Lee J, Choi S, Blaize G, Argenty J, Familiades J, Li L, Gonzalez de Peredo A, Burlet-Schiltz O, Love PE, Lesourne R. *Themis1 enhances T cell receptor signaling during thymocyte development by promoting Vav1 activity and Grb2 stability*. **Sci Signal**. 2016 May 17;9(428):ra51. doi: 10.1126/scisignal.aad1576.